Jade Biosciences, Inc.
JBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 53.52 | -0.22 | -0.11 | -0.09 |
| FCF Yield | -0.06% | -9.55% | -5.48% | -9.58% |
| EV / EBITDA | 0.00 | -7.60 | -13.53 | -10.21 |
| Quality | ||||
| ROIC | -116.90% | -73.93% | -41.64% | -13.31% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.02 | 0.75 | 0.76 | 1.19 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | 99.92% | -44.77% | -42.56% | -250.94% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.30 | 0.41 | 2.34 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1.67 | -9,109.79 | -13,821.69 | -29,394.67 |